![COVID-19: Comparison of the Response in Rwanda, South Africa, and Zimbabwe](https://icap.columbia.edu/wp-content/uploads/tai-s-captures-Lhb-zwQ-QGI-unsplash-1080x675.jpg)
Zimbabwe
![COVID-19: Comparison of the Response in Rwanda, South Africa, and Zimbabwe](https://icap.columbia.edu/wp-content/uploads/tai-s-captures-Lhb-zwQ-QGI-unsplash-1080x675.jpg)
![COVID-19 and its Intersect with Ethics and Human Rights in sub-Saharan Africa](https://icap.columbia.edu/wp-content/uploads/fusion-medical-animation-EAgGqOiDDMg-unsplash-1080x675.jpg)
COVID-19 and its Intersect with Ethics and Human Rights in sub-Saharan Africa
Farirai Mutenherwa, Rouzeh Eghtessadi, Tafadzwa Dzinamarira, Godfrey Musuka. “COVID-19 and its intersect with ethics and human rights in Sub-Saharan Africa.” The Journal of Infection in Developing Countries, 2021; 15(7):910-912. doi:10.3855/jidc.1479. ...![Special Webinar (Archived Recording) — Population Surveys: Measuring and Informing the HIV Response](https://icap.columbia.edu/wp-content/uploads/Webinar-Recordings-e1532366618694-1080x675.png)
Special Webinar (Archived Recording) — Population Surveys: Measuring and Informing the HIV Response
RECORDED: Thursday, July 1, 2021, 9:00 – 10:30 a.m. ET ACCESS THE RECORDING ACCESS THE SLIDES, including Q&A On Thursday, July 1, 2021, ICAP at Columbia University hosted a webinar to discuss population surveys and how their findings provide critical information...![Targeting those left behind in Zimbabwe’s HIV response: A call for decriminalisation of key populations to rapidly achieve 95-95-95 targets](https://icap.columbia.edu/wp-content/uploads/51138037313_eb75755b4b_o-e1623766668770-1080x675.jpg)
Targeting those left behind in Zimbabwe’s HIV response: A call for decriminalisation of key populations to rapidly achieve 95-95-95 targets
Musuka, G., & Dzinamarira, T. (2021). Targeting those left behind in Zimbabwe’s HIV response: A call for decriminalisation of key populations to rapidly achieve 95-95-95 targets. South African Medical Journal, 111(5), 385. doi:10.7196/SAMJ.2021.v111i5.15567 To the...![May 2021: Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis](https://icap.columbia.edu/wp-content/uploads/0-3-e1622128820264-1080x675.png)